Ann: Quarterly Activities Report and Appendix 4C - March 2024, page-6

Stormer, you are allowed to send an email to chairman DW expressing your frustrations and concerns and perhaps asking that as a SH, how he plans to address the situation, he usually answers. It's difficult not to get frustrated as there is so much potential, and the price has been a lot higher as Innoviq, and much, much higher prior to the renaming when it existed as Bard1, but it is still a speculative biotech so the SP is volatile and super reactive to announcements both positive and negative. I agree that a change is needed, and do think that the current chair is the right person for the job, we will see, stay well